Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Metacycline→

Metacycline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
914-00-1
Molecular formula
C22H22N2O8
Molecular weight
442.4 g/mol
Drug class
Tetracycline-class antibacterial30S ribosomal protein-synthesis inhibitor
Mechanism of action
Reversibly binds to the bacterial 30S ribosomal subunit and prevents aminoacyl-tRNA from binding to the acceptor site on the mRNA-ribosome complex, inhibiting bacterial protein synthesis and producing bacteriostatic activity.
Indications / reported uses
  • Treatment of susceptible bacterial infections in countries where metacycline is authorised; indication depends on local product information and susceptibility.

Sources: https://www.ncbi.nlm.nih.gov/books/NBK549905/ · https://pubchem.ncbi.nlm.nih.gov/compound/Metacycline · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Metacycline Environmental Risk Assessment (ERA) (the Metacycline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.